bioihbjkbjnl/mcl2 huggingface dataset:
Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)
Condition: Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage IIIA
MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Study type: Observational

Summary: 
      In pre-clinical study, we found that serum thioredoxin reductase activity harbours huge
      difference after any kind of treatments, so we hypothesis that serum activity of thioredoxin
      reductase may be a warning markers in excised non-small lung cancers, serum activity of this
      enzyme may elevated before CT scan
    

Detailed description: 
      This is a cooperative research project in Thoracic Surgery Department and Medical Oncology
      department of Affiliated Cancer Hospital of xiangya School of Medicine Central South
      University, and the State Key Laboratory for Natural Medicine and Biomimetic Drugs Perking
      University. The primary objective is to measure the thioredoxin reductase activity in blood
      in staged(Ⅰ~ⅢA) non-small lung cancers, to study the warning relapse ability of thioredoxin
      reductase in blood. The secondary objective is to compare the warning relapse activity of
      blood thioredoxin reductase activity with carcinoembryonic antigen (CEA) in subjects who
      received surgery. Blood will be collected in subjects before surgery, 5 days after surgery,
      and every 3 months after surgery till 2 years, then every 6 months till 3 years, or collect
      blood till tumor relapse for the subjects at stage ⅠA and low risk ⅠB. Blood will be
      collected before surgery, 5 days after surgery, before adjuvant chemotherapy, after 2 circles
      of all adjuvant chemotherapy, then every 3 months after adjuvant chemotherapy till 2 years,
      and every 6 months till 3 years, or collect blood till tumor relapse for the subjects of high
      risk ⅠB~ⅢA, evaluation CT results every time collect blood samples.
    

Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patients diagnosed with resectable non-small lung cancer and received surgery in Affiliated
        Cancer Hospital of xiangya School of Medicine Central South University, HunanPTH
      
Biospecimen description: 
      3-4 ml whole blood was obtained and then centrifuged and stored at -20℃.
    
Keywords: non-small cell lung cancer; thioredoxin reductase; carcina embryonic antigen
Propylene Glycol/Glycerol Intake and Cardiorespiratory Function
Condition: Lung Injury
MeSH terms: Lung Injury
Study type: Interventional

Summary: 
      Propylene glycol/Glycerol intake is increasingly popular. The propylene glycol/glycerol
      intake effects on cardiorespiratory function are unknown.
    

Detailed description: 
      Background. Propylene glycol/Glycerol intake is increasingly popular. The propylene
      glycol/glycerol intake effects on cardiorespiratory function are unknown. Weaning of
      propylene glycol/glycerol could allows a quick clearance of propylene glycol/glycerol from
      the body, with subsequent recovery of cardiorespiratory function.

      Specific aim of the research. This research proposal tests the following hypothesis regarding
      the reversibility of propylene glycol/glycerol and nicotine intake:

        -  Propylene glycol/glycerol cessation restores cardiorespiratory function.

        -  Chronic propylene glycol/glycerol and propylene glycol/glycerol/nicotine intake induces
           specific serum and urine proteomics profile, which are partially reversed after
           cessation.

        -  Chronic propylene glycol/glycerol and propylene glycol/glycerol/nicotine intake induces
           specific serum and urine metabolomics profile, which are partially reversed after
           cessation.
    

Intervention name(s): Nicotine free intake; Nicotine intake; Cessation intake
Intervention type(s): Other; Other; Other
Intervention description(s): The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.; The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.; The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
Intervention MeSH terms: Nicotine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary purpose: Basic Science
Is Preoperative Exercise Test in Morbid Obese Patients a Predictive Test for Extubation?
Condition: Morbid Obesity
MeSH terms: Obesity, Morbid
Study type: Interventional

Summary: 
      the purpose of this study is to determine if 60 meter test done prior to surgery is a
      predictive in terms of extubation in morbid obese patients undergoing morbid obese surgery.
    


Intervention name(s): walk test
Intervention type(s): Other
Intervention description(s): patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
Other intervention name(s): 60 meter walk test
Intervention model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Diagnostic
Keywords: morbid obesity surgery; walk test; exercise
Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam
Condition: Alcohol Withdrawal Syndrome(AWS)
MeSH terms: Syndrome; Substance Withdrawal Syndrome
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study was to evaluate if the medication Gabapentin, which is not approved
      for the treatment of alcohol withdrawal, is effective in the treatment of alcohol withdrawal
      syndrome compared to treatment with Lorazepam.
    

Detailed description: 
      In the current protocol we evaluated a newer generation anticonvulsant agent, gabapentin.
      Gabapentin does not significantly interact with alcohol or other medications, has no abuse
      potential, and is excreted by the kidneys and not the liver .

      The primary aim of the present application was to evaluate the efficacy of gabapentin in
      comparison to lorazepam (as a benzodiazepine gold standard) for the acute outpatient
      treatment of alcohol withdrawal (AW). In addition, evaluation of the lorazepam "rebound"
      effects observed during the current funding period will be replicated and compared with the
      response to gabapentin. Also, the acoustic startle response was used to evaluate the
      neurobiological effects of the medications on underlying AW-related CNS excitation, both
      during and immediately after AW. In addition, the effect of a history of multiple
      detoxifications on parameters such as withdrawal symptoms, CNS excitability, relapse to
      alcohol use, craving for alcohol, and response to medication treatment was explored.
    

Intervention name(s): Gabapentin; Lorazepam
Intervention type(s): Drug; Drug
Intervention MeSH terms: Gabapentin; Lorazepam
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Alcohol Withdrawal Syndrome; CIWA-Ar; Acoustic Startle Procedure; Rebound Effect
Fetal Lung Volume and Pulmonary Artery Resistance Index Measurement in Term Diabetic Pregnancy
Condition: Respiratory Distress Syndrome
MeSH terms: Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Pregnancy in Diabetics
Study type: Observational

Summary: 
      The aim of this study is to determine cut-off values for fetal lung volume by VOCAL and
      pulmonary artery resistance index by pulsed Doppler in fetuses of diabetic mothers, and
      correlate the results with postnatal respiratory distress of the term neonates.
    

Detailed description: 
      Research question:

      Can the assessment of fetal lung volume by Virtual Organ Computed-aided Analysis (VOCAL) and
      pulmonary artery resistance index by pulsed Doppler predict neonatal respiratory distress
      syndrome in term fetuses of diabetic mothers?

      Research hypothesis:

      The assessment of fetal lung volume by VOCAL and pulmonary artery resistance index by pulsed
      Doppler can predict neonatal respiratory distress syndrome in term fetuses of diabetic
      mothers.
    

Intervention name(s): Three-dimensional (3D) ultrasonography
Intervention type(s): Device
Intervention description(s): A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        This is a prospective observational study which will be carried out at Ain Shams University
        Maternity Hospital, Obstetrics and Gynecology department, Faculty of Medicine, Ain Shams
        University, from December 2015 to December 2016.

        Diabetic pregnant women 38 weeks gestation admitted for elective termination by Caesarian
        section due to various obstetric indications
A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)
Condition: Breast Neoplasm
MeSH terms: Breast Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to evaluate, in a first stage, the safety (incidence of cardiac
      toxicity) of Caelyx in combination with Trastuzumab and Docetaxel; and in a second stage, the
      tumor response rate of this regimen. This study will be conducted in approximately 30
      centers. A total of approximately 70 to 95 subjects will be enrolled.
    


Intervention name(s): Pegylated Liposomal Doxorubicin; Docetaxel; Trastuzumab
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks
Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks.; Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.; Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
Other intervention name(s): Caelyx; Taxotere
Intervention MeSH terms: Docetaxel; Doxorubicin; Liposomal doxorubicin; Trastuzumab
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Pilot Study: Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve
Condition: Postoperative Ileus
MeSH terms: Ileus
Study type: Interventional

Summary: 
      Hypothesis:

      Electrical stimulation of the abdominal vagus nerve has an anti-inflammatory effect and
      represents a new therapeutic approach to shorten postoperative ileus.

      Aims:

      In the present pilot study, the investigators want to evaluate the anti-inflammatory effect
      of peroperative electrical stimulation of the vagus nerve. To this end, the following aims
      are formulated:

        1. to optimize the technique of intra-operative electrical vagus nerve stimulation

        2. to show that electrical stimulation of the intra-abdominal vagus nerve reduces the
           inflammatory response to abdominal surgery

        3. to evaluate whether electrical stimulation of the vagus nerve leads to clinical
           improvement (collect pilot data)
    


Intervention name(s): Vagus stimulation 1; Vagus stimulation 2
Intervention type(s): Procedure; Procedure
Intervention description(s): 2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA; 2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Single Photon Emission Computed Tomography of the Normal Human Brain
Condition: Normal Human Subjects
Study type: Observational

Summary: 
      The objective of the study is to acquire a database of Single Photon Emission Computed
      Tomographic (SPECT) studies of the brains of normal human subjects in resting and
      concentrating states. The database will provide a basis for subsequent investigation of
      meaningful brain differences between clinical and normal subject groups
    

Detailed description: 
      See brief summary.
    

Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        The study seeks to recruit 100 subjects between ages 10 and 90 for SPECT brain imaging.
      
Keywords: SPECT; Imaging; Healthy brain; regional cerebral blood flow
Vaginal Heat Wash-out (HWO) in 4 Groups of Women (Pre- and Postmenopausal With and Without Female Sexual Arousal Disorder (FSAD)).
Condition: Sexual Dysfunction, Physiological
MeSH terms: Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological
Study type: Interventional
Phase: Phase 1

Summary: 
      The Pfizer developed Heat Wash-Out (HWO) system is a software controlled electromechanical
      system designed to measure vaginal wall blood flow. A small vaginal probe is attached to a
      control unit. Output data are collected on a PC. By measuring the clearance of heat from the
      heated probe, a direct measure of absolute blood flow can be obtained. The study will assess
      the technique's ability to differentiate between pre- and post-menopausal women; with and
      without Female Sexual Arousal Disorder (FSAD).
    

Detailed description: 
      Medical Device Development
    

Intervention name(s): Vaginal Heat Wash-Out Device
Intervention type(s): Device
Intervention description(s): No drug administered. Device tested twice with each subject.
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Other
Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions
Condition: Healthy
MeSH terms: Malnutrition
Study type: Interventional

Summary: 
      The objective of this study was to compare the single-dose relative bioavailability of
      Ranbaxy and Schering (Claritin-D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate
      Extended-Release Tablets, in a fully replicated design, under fed conditions.
    

Detailed description: 
      The study was conducted as an open-label, randomized, Single-Dose, Fully replicated, 4-way
      Crossover Study to compare the single-dose relative bioavailability of Ranbaxy and Schering
      (Claritin_D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release
      Tablets, in Healthy adult Volunteers Under Fed Conditions In each period, subjects were
      housed from the evenings before the dosing until after the 36 hour blood draw and were to
      return for subsequent blood draws at 48, 72, 96 and 120 hours post dose. Single oral 10 mg
      Loratadine/ 240 mg Pseudoephedrine Sulfate doses were separated by a washout period of 21
      days.

      A total of 40 subjects and 1 alternate (34 males and 7 females) were included in this study,
      of which 37 (32 males and 5 females) finished the study according to the protocol.
    

Intervention name(s): 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
Intervention type(s): Drug
Intervention MeSH terms: Loratadine; Pseudoephedrine; Ephedrine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Keywords: Bioequivalence 10 mg Loratadine 240 mg Pseudoephedrine Sulfate Extended Release Tablets
Prognostic and Predictive Impact of uPA/PAI-1
Condition: Breast Cancer
MeSH terms: Breast Neoplasms
Study type: Interventional
Phase: Phase 3

Summary: 
      Chemo-N0 (1993-1998) is the first prospective randomized multicenter trial in N0 BC designed
      to prospectively evaluate the clinical utility of a biomarker. It used uPA/PAI 1 as
      stratification criteria and randomized high-risk patients to chemotherapy versus observation;
      low-risk patients remained without any systemic therapy. The trial was designed to answer two
      principle questions:

        1. Can the reported prognostic impact of uPA and PAI 1 be validated in a prospective
           multicenter therapy trial? Does low uPA/PAI 1 identify those low-risk N0 patients who
           are candidates for being spared necessity and burden of adjuvant chemotherapy?

        2. Do uPA/PAI 1 high-risk patients benefit from adjuvant CMF chemotherapy?
    


Intervention name(s): CMF Chemotherapy
Intervention type(s): Drug
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: node-negative
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Condition: Brain and Central Nervous System Tumors
MeSH terms: Glioma; Nervous System Neoplasms; Central Nervous System Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood
      flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from
      dividing so they stop growing or die. Combining thalidomide and celecoxib with etoposide and
      cyclophosphamide may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and celecoxib
      with etoposide and cyclophosphamide in treating patients who have relapsed or refractory
      malignant glioma.
    

Detailed description: 
      OBJECTIVES:

        -  Determine the efficacy of thalidomide, celecoxib, etoposide, and cyclophosphamide, in
           terms of 6-month progression-free survival, in patients with relapsed or refractory
           malignant glioma.

        -  Determine the overall survival of patients treated with this regimen.

        -  Determine the toxic effects of this regimen in these patients.

        -  Determine the radiographic response in patients treated with this regimen.

      OUTLINE: This is a multicenter study.

      Patients receive oral thalidomide once daily and oral celecoxib twice daily on days 1-42,
      oral etoposide once daily on days 1-21, and oral cyclophosphamide once daily on days 22-42.
      Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 2 months.

      PROJECTED ACCRUAL: A total of 48 patients (32 with glioblastoma multiforme and 16 with
      anaplastic glioma) will be accrued for this study within 2 years.
    

Intervention name(s): celecoxib; cyclophosphamide; etoposide; thalidomide
Intervention type(s): Drug; Drug; Drug; Drug
Intervention MeSH terms: Thalidomide; Celecoxib; Cyclophosphamide; Etoposide
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: adult anaplastic astrocytoma; adult anaplastic oligodendroglioma; adult glioblastoma; adult mixed glioma; recurrent adult brain tumor; adult giant cell glioblastoma; adult gliosarcoma
Masotherapy With Neural Tension in Patients With Parkinson's Disease
Condition: Parkinson Disease
MeSH terms: Parkinson Disease
Study type: Interventional

Summary: 
      The objective of this study is to assess if the masotherapy with neural tension is more
      effective than non-neural tension to improve and reduce tremor in patients with Parkinson's
      disease. The project will be carried out in clinics, where both data collection, assessments
      and scales will be carried out, as well as the plan and intervention in which the neural
      tension massage therapy of the radial nerve will be applied to the first intervention group;
      and massage therapy without neural tension in the second group.
    

Detailed description: 
      In this study the investigators are going to compare the effectiveness of two treatments
      (masotherapy with neural tension and masotherapy with non-neural tension) in patients with
      Parkinson disease based on the improved of pain, tremor, functional and life quality.

      The investigators are going to divide the number of volunteers in two groups. The first group
      is going to be treated during 8 weeks with conventional (non-neural tension) masotherapy in
      the upper limb, the other group is going to be treated with radial neural tension masotherapy
      during 8 weeks also. To apply the neural tension, the investigators position the patient's
      upper limb lowering the scapula, elbow extended, internal rotation glenohumeral, forearm
      pronation, bend and cubital deviation of the wrist, fingers bended and thumb adduction, and
      finally glenohumeral abduction.

      To compare the results between the different groups, the investigators are going to value the
      patients 4 times, the first one before the beginning of the treatment, the second one and the
      end of the treatment, the third one after one month completing the treatment, and the last
      one after three months completing the treatment.
    

Intervention name(s): Masotherapy with neural tension and masotherapy with non-neural tension
Intervention type(s): Procedure
Intervention description(s): To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
Other intervention name(s): Neurodynamic
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
Primary purpose: Treatment
Keywords: Parkinson disease; Essential tremor; Neuromuscular Therapy; Massage; Manual Therapy; Neurodynamic